1. A pharmaceutical composition characterized in that it comprises an activated - potentiated form of antibodies to brain-specific proteins and S-100 activated - potentiated form of antibodies to endothelial NO-sintaze.2. A pharmaceutical composition according to claim 1, characterized in that the activated - potentiated form of antibodies to brain-specific proteins and S-100 activated - potentiated form of antibodies to endothelial NO-synthase is used in activated form - potentiated aqueous or hydroalcoholic solution, which activity is due to the process multiple serial dilution in an aqueous or aqueous-alcoholic solvent with an external mechanical impact - each razvedeniya.3 shaking. A pharmaceutical composition according to claim 1, characterized in that it is made in a solid dosage form contains an effective amount of a neutral carrier granules saturated with water or with a mixture of aqueous-alcoholic solutions of the activated - potentiated form of antibodies to S-100 protein and a brain-specific activated - potentiated form of antibodies to endothelial NO-synthase, and a pharmaceutically acceptable dobavki.4. A pharmaceutical composition according to claim 2, characterized in that aqueous or hydroalcoholic solutions of activated - potentiated forms of antibodies to brain-specific proteins and S-100 in endothelial NO-synthase obtained by multiple successive dilution in combination with external action - shaking of each dilution matrix solutions of affinity purified antibodies to brain-specific proteins and S-100 in endothelial NO-synthase with con1. Фармацевтическая композиция, характеризующаяся тем, что содержит активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе.2. Фармацевтическая композиция по п.1, характеризующаяся тем, что активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антите
